Fig. 8

SMAD3 from CAFs reduces the radiosensitivity of NSCLC cells by activating the ITGA6/PI3K/Akt pathway. A The expression of SMAD3 and ITGA6 in H460 cells treated with sh-ITGA6 + oe-SMAD3 or sh-ITGA6 + CAF-CM and in the H1229 cells treated with sh-SMAD3 + oe-ITGA6 determined by RT-qPCR. B Western blot of SMAD3, ITGA6 and the PI3K/Akt pathway-related proteins in H460 cells treated with sh-ITGA6 + oe-SMAD3 or sh-ITGA6 + CAF-CM and in the H1229 cells treated with sh-SMAD3 + oe-ITGA6. C Viability of H460 cells treated with sh-ITGA6 + oe-SMAD3 or sh-ITGA6 + CAF-CM and of H1229 cells treated with sh-SMAD3 + oe-ITGA6 following exposure to 6 Gy X-ray radiation measured by CCK-8. D Colony formation of H460 cells treated with sh-ITGA6 + oe-SMAD3 or sh-ITGA6 + CAF-CM and of H1229 cells treated with sh-SMAD3 + oe-ITGA6, following exposure to 6 Gy X-ray radiation. E Invasion of H460 cells treated with sh-ITGA6 + oe-SMAD3 or sh-ITGA6 + CAF-CM and of H1229 cells treated with sh-SMAD3 + oe-ITGA6, following exposure to 6 Gy X-ray radiation. F γH2ax fluorescence in H460 cells treated with sh-ITGA6 + oe-SMAD3 or sh-ITGA6 + CAF-CM and in H1229 cells treated with sh-SMAD3 + oe-ITGA6, following exposure to 6 Gy X-ray radiation. G Apoptosis of H460 cells treated with sh-ITGA6 + oe-SMAD3 or sh-ITGA6 + CAF-CM and of H1229 cells treated with sh-SMAD3 + oe-ITGA6, following exposure to 6 Gy X-ray radiation determined by flow cytometry. H Cell cycle distribution of H460 cells treated with sh-ITGA6 + oe-SMAD3 or sh-ITGA6 + CAF-CM and of H1229 cells treated with sh-SMAD3 + oe-ITGA6, following exposure to 6 Gy X-ray radiation determined by flow cytometry. *p < 0.05 vs. oe-SMAD3 + sh-NC group. ^#p < 0.05 vs. CAF-CM + sh-NC group. ^&p < 0.05 vs. sh-SMAD3 + oe-NC group. Cell experiments were repeated three times